<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01977170</url>
  </required_header>
  <id_info>
    <org_study_id>Hib 0110</org_study_id>
    <nct_id>NCT01977170</nct_id>
  </id_info>
  <brief_title>Safety of Hib Vaccine (Bio Farma)</brief_title>
  <official_title>Phase 1 Study of Hib Vaccine (Bio Farma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to know the safety of Hib/PRP-T vaccine and immediate
      reactions within the first 30 minutes after injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial was an open-label study, no randomization, and no placebo or control group. Total
      25 young healthy adult (volunteers) followed this trial. The safety was assessed within 24
      hours, 48 hours, 72 hours, and 28 days after injection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of adverse event of Hib vaccine (Bio Farma)</measure>
    <time_frame>30 minutes</time_frame>
    <description>Local and systemic reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the antibody function serum using serum bactericidal activities test</measure>
    <time_frame>28 days</time_frame>
    <description>Presence of serum of bactericidal activities after immunization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of adverse event of Hib vaccine (Bio Farma)</measure>
    <time_frame>28 hours, 48 hours, 72 hours, 28 days</time_frame>
    <description>Local and systemic reaction</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Hib/PRP-T vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose, correspond to 0.5 ml, composed of:
PRP-T 10ug NaCl 0.85%
Frequency: 1 injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hib/PRP-T vaccine</intervention_name>
    <description>Hib liquid vaccine</description>
    <arm_group_label>Hib/PRP-T vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (age 18 - 40 years old)

          -  Provision of written informed consent

          -  Good health according to the clinical investigator

          -  Willingness and ability to adhere to the regimen of the study

        Exclusion Criteria:

          -  Known not enrolled in other study

          -  Pregnancy or lactation

          -  Known or suspected allergy to any of the vaccine component (by medical history)

          -  History of unusual reaction to any previous vaccination

          -  Known or suspected immune deficiency, or use of medication that may influence the
             immune system

          -  Prior respiratory infection

          -  Other vaccination during the study, or one week before (inactivated vaccine) or one
             month (live vaccine) before the study

          -  Acute febrile illness (temperature &gt; 37.5 Celsius)

          -  Present evidence of serious diseases demanding medical treatment

          -  Any significant congenital or chronic disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kusnandi Rusmil, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine UNPAD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hasan Sadikin Hospital</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <zip>40161</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2013</study_first_submitted>
  <study_first_submitted_qc>November 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2013</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adults</keyword>
  <keyword>Hib vaccines</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

